Patents by Inventor Andrew Bolt

Andrew Bolt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12257529
    Abstract: The present invention relates to the extraction of lithium from liquid resources such as natural and synthetic brines, leachate solutions from clays and minerals, and recycled products with the assistance of an alternate phase.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: March 25, 2025
    Assignee: LILAC SOLUTIONS, INC.
    Inventors: David Henry Snydacker, Nicolás Andrés Grosso Giordano, Amos Indranada, Alysia Lukito, Sean Utan, Mustafa Juzer Bootwala, Daniel Keane Laporte, Andrew Bolt Barber, Christina Fleming, Garrett Lau
  • Publication number: 20240026495
    Abstract: The present invention relates to the extraction of lithium from liquid resources such as natural and synthetic brines, leachate solutions from clays and minerals, and recycled products with the assistance of an alternate phase.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 25, 2024
    Inventors: David Henry SNYDACKER, Nicolás Andrés GROSSO GIORDANO, Amos INDRANADA, Alysia LUKITO, Sean UTAN, Mustafa Juzer BOOTWALA, Daniel Keane LAPORTE, Andrew Bolt BARBER, Christina FLEMING, Garrett LAU
  • Publication number: 20170023577
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: March 25, 2016
    Publication date: January 26, 2017
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Publication number: 20090181393
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: December 16, 2008
    Publication date: July 16, 2009
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Publication number: 20060129765
    Abstract: A test system, method and a computer program product are provided for testing software to be run on a data processing apparatus having a plurality of processors operable to share access to a memory system, where at least a part of the memory system has a memory ordering type which allows memory access requests at that part to be processed out of order from an original program order. The test system comprises a processor simulator for each processor of the data processing apparatus, each processor simulator being operable to execute a sequence of instructions in program order. Further, at least one access buffer unit is provided, each access buffer unit being associated with one of the processor simulators and being operable to receive memory access requests issued by that processor simulator when executing memory access instructions within the sequence of instructions.
    Type: Application
    Filed: November 29, 2004
    Publication date: June 15, 2006
    Inventors: Andrew Rose, Andrew Bolt, Donald Sinclair
  • Publication number: 20040156854
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: December 4, 2003
    Publication date: August 12, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Publication number: 20020110815
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
    Type: Application
    Filed: April 13, 2001
    Publication date: August 15, 2002
    Inventors: James Lillie, Jeffrey Brown, Andrew Bolt, Christophe Van Huffel
  • Publication number: 20020081596
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
    Type: Application
    Filed: March 22, 2001
    Publication date: June 27, 2002
    Inventors: James Lillie, Jeffrey Brown, Andrew Bolt, Christophe Van Huffel